Mahesh K B Parmar
Oncology · 2002–2017
A researcher in the Science corpus: 15 papers; trusts 2 researchers and is trusted by 10 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 63 citations into it
- Statistics and Probability — 9 citations into it; #4,111 of 12,932 by trust here, #4,014 by citations
Whom Mahesh K B Parmar trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Mahesh K B Parmar overall
Papers from Mahesh K B Parmar's perspective
Ordered by how strongly the researchers Mahesh K B Parmar trusts endorse each paper. Same corpus, a different order for every researcher.
- Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model
- Further Development of Flexible Parametric Models for Survival Analysis
- The Statistical Analysis of Failure Time Data (Technometrics)
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study (The Lancet)
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma (Cancer)
- A phase 3 trial of bevacizumab in ovarian cancer. (New England Journal of Medicine)
- Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
- Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. (Controlled Clinical Trials)
- Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study (Cancer Causes and Control)
Their papers
- Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects (2002) — 1,510 citations
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) — 2,021 citations
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. (2017) — 2,819 citations
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017) — 1,576 citations
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (2016) — 1,799 citations
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial (2015) — 794 citations
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome (2013) — 974 citations
- International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. (2011) — 842 citations
- Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials (2011) — 44 citations
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) (2010) — 597 citations
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial (2009) — 1,448 citations
- Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial (2009) — 1,023 citations
- Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. (2008) — 890 citations
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. (2007) — 924 citations
- Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. (2007) — 598 citations